

GONORRHEA

References

1. Surveillance and Epidemiology Section, Community Acquired Infections Division, Public Health Agency of Canada, unpublished data, 2006.
2. Tapsall JW, Limnios EA, Shultz TR. Continuing evolution of the pattern of quinolone resistance in *Neisseria gonorrhoeae* isolated in Sydney, Australia. *Sex Transm Dis* 1998;25:415–417
3. Ng LK, Sawatzky P, Martin IE, Booth S. Characterization of ciprofloxacin resistance in *Neisseria gonorrhoeae* isolates in Canada. *Sex Transm Dis* 2002;29:780–788
4. Mann J, Kropp R, Wong T, et al. Gonorrhea treatment guidelines in Canada: 2004 update. *CMAJ* 2004;171:1345–1346.
5. Sarwal S, Wong T, Sevigny C, Ng LK. Increasing incidence of ciprofloxacin resistant *Neisseria gonorrhoeae* infection in Canada. *CMAJ* 2003;168:872–873.
6. National Microbiology Laboratory, Public Health Agency of Canada, unpublished data, 2004.
7. Laga M, Manoka A, Kivuvu M, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women; results from a cohort study. *AIDS* 1993;7:95–102.
8. De P, Singh AE, Wong T, Kaida A. Predictors of gonorrhea reinfection in a cohort of sexually transmitted disease patients in Alberta, Canada, 1991-2003. *Sex Transm Dis* 2007;34:30-6.
9. Sung L, MacDonald NE. Gonorrhea: a pediatric perspective. *Pediatr Rev* 1998;19:13–22.
10. Korenromp EL, Sudaryo MK, de Vlas SJ, et al. What proportion of episodes of gonorrhea and chlamydia become symptomatic? *Int J STD AIDS* 2002;13:91–101.
11. Mehta SD, Rothman RE, Kelen GD, Quinn TC, Zenilman JM. Clinical aspects of diagnosis of gonorrhea and chlamydia infection in an acute care setting. *Clin Infect Dis* 2001;32:655–659.
12. Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections — 2002. *MMWR Recomm Rep* 2002;51(RR-15):1–38.
13. Davies PO, Low N, Ison CA. The role of effective diagnosis for the control of gonorrhoea in high prevalence populations. *Int J STD AIDS* 1998;9:435–443.
14. Koumans EH, Johnson RE, Knapp JS, St. Louis ME. Laboratory testing for *Neisseria gonorrhoeae* by recently introduced nonculture tests: a performance review with clinical and public health considerations. *Clin Infect Dis* 1998;27:1171–1180.
15. Bachmann LH, Desmond RA, Stephens J, Hughes A, Hook EW 3rd. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. *J Clin Microbiol* 2002;40:3596–3601.
16. McCormack WM, Stumacher RJ, Johnson K, Donner A. Clinical spectrum of gonococcal infections in women. *Lancet* 1977;1:1182–1185.
17. Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? *Clin Infect Dis* 2002;35(suppl 2):S191–S199.

18. Dan M, Poch F, Sheinberg B. High prevalence of high-level ciprofloxacin resistance in *Neisseria gonorrhoeae* in Tel Aviv, Israel: correlation with response to therapy. *Antimicrob Agents Chemother* 2002;46:1671–1673.
19. Apasca de los Reyes MR, Pato-Mesola V, Klausner JD, et al. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in the Philippines. *Clin Infect Dis* 2001;32:1313–1318.
20. Jones RB, Schwebke J, Thorpe EM Jr, Dalu ZA, Leone P, Johnson RB. Randomized trial of trovafloxacin and ofloxacin for single dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group. *Am J Med* 1998;104:28–32.
21. Stoner BP, Douglas JM Jr, Martin DH, et al. Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial. *Sex Transm Dis* 2001;28:136–142.
22. Robinson AJ, Ridgway GL. Concurrent gonococcal and chlamydial infection: how best to treat. *Drugs* 2000;59:801–813.
23. Tapsall J. Current concepts in the management of gonorrhoea. *Expert Opin Pharmacother* 2002;3:147–157.
24. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. *Sex Transm Dis* 1994;21:107–111.
25. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD Jr. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. *Am J Obstet Gynecol* 2001;185:629–632.
26. Donders GG. Treatment of sexually transmitted bacterial diseases in pregnant women. *Drugs* 2000;59:477–485.
27. Brocklehurst P. Update on the treatment of sexually transmitted infections in pregnancy — 1. *Int J STD AIDS* 1999;10:571–578.
28. American Academy of Pediatrics. Committee on Child Abuse and Neglect. Gonorrhea in prepubertal children. *Pediatrics* 1998;101(1 Pt 1):134–135.
29. Sorensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schonheyder HC. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. *Scand J Infect Dis* 2003;35:104–106.
30. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. *Arch Pediatr Adolesc Med* 2002;156:647–650.
31. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. *J Pediatr* 2001;139:380–384.
32. Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. *Lancet* 1999;354:2101–2105.